Platelet Rich Plasma and Neural Prolotherapy Injections in Treating Knee Osteoarthritis
Primary Purpose
Knee Osteoarthritis
Status
Unknown status
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
Autologous platelet rich plasma and dextrose solution.
Sponsored by
About this trial
This is an interventional treatment trial for Knee Osteoarthritis focused on measuring platelet rich plasma; neural prolotherapy
Eligibility Criteria
Inclusion Criteria:
- Patients suffered from chronic unilateral knee pain for more than 4 months and with roentgenogram degenerative findings of grades 3 and 4 on the Kellgren-Lawrence Classification of Osteoarthritis scale (meaning moderate to severe degrees of knee OA) will be recruited.
- The volume of the SF in the supra-patellar bursa region is enough (at least 2 mm thickness in bursa fluid as measured by ultrasound) to be aspirated via ultrasound guidance.
- Small volume of SF will be aspirated first and sent for SF analysis. SF showing evidences of crystals suggesting possible gouty arthritis and infection will not be included in this study.
- Patient has previously received oral NSAIDs and physical modality treatments but WITHOUT any obvious improvements in knee pain and function.
- The usage of musculoskeletal ultrasound to confirm that the supra-patellar bursa is in communication with the synovial cavity of the knee joint. This is to prevent the aspiration of isolated cystic lesion at the supra-patellar region.
Exclusion Criteria:
- Total obliteration of knee joint as shown on the roentgenogram images.
- Patient has systemic disorders such as diabetes, rheumatoid arthritis, major axial deviation of the knee joint (varus >5°, valgus >5°), hematological diseases (coagulopathy), severe cardiovascular diseases, infections, and immune-depression.
- Patients in therapy with anticoagulants, and taking NSAIDs within the 5 days before blood harvest.
- Patients with hemoglobin value of less than 11 g/dl, and platelet counts of less than 150,000/mm3.
Sites / Locations
- Chang Gung Memorial HospitalRecruiting
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Receiving PRP injections or PRP plus neural prolotherapy
Arm Description
PRP injection into the knee joint and pes anserinus complex. Dextrose solution to the genicular nerves.
Outcomes
Primary Outcome Measures
Lequesne knee osteoarthritis questionnaire
Lequesne knee osteoarthritis functional index which includes distance, pain, and function.
Two-dimensional electrophoresis (proteomics)
Hundreds of protein spots can be viewed on 2-dimensional electrophoresis gels. The intensity of each spot represents protein concentration.
Secondary Outcome Measures
Full Information
NCT ID
NCT04006314
First Posted
June 26, 2019
Last Updated
July 1, 2019
Sponsor
Chang Gung Memorial Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04006314
Brief Title
Platelet Rich Plasma and Neural Prolotherapy Injections in Treating Knee Osteoarthritis
Official Title
Exploring the Effectiveness of Simultaneous Autologous Platelet Rich Plasma and Neural Prolotherapy Injections in Treating Patients With Moderate to Severe Degrees of Knee Osteoarthritis
Study Type
Interventional
2. Study Status
Record Verification Date
June 2019
Overall Recruitment Status
Unknown status
Study Start Date
September 4, 2018 (Actual)
Primary Completion Date
July 31, 2020 (Anticipated)
Study Completion Date
July 31, 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chang Gung Memorial Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Osteoarthritis (OA) of the knees is the most common degenerative disorder seen in a rehabilitation outpatient clinic. It is characterized by metabolic, biochemical, and structural changes in the articular cartilage and the surrounding tissues. Knee OA patients are often troubled with knee pain and functional disturbance. Several studies have shown that the earlier the injection of autologous platelet rich plasma (a PRP) to treat early stages of knee OA, the better the treatment outcome. However, no consensus has been reached as to whether PRP injection is beneficial for patients with moderate to severe degrees of knee OA. Studies have also shown that the application of neural prolotherapy (NPT) to the genicular nerves may have beneficial effects in treating patients with severe knee OA. However, patients may start to walk for a longer period of time due to reduced knee pain after NPT. If the regenerative effect of PRP is not yet obvious on the knee cartilage, this excess walking may result in further destruction of the knee joints. No studies have examined the combined treatment effect of a PRP and NPT on patients with moderate to severe degrees of knee OA.
NPT is the injection of low percentage dextrose water (5%) with the rationale to repair and reduce pain caused by the nerves. We would like to bring our PRP study to a higher level by conducting a two-year study to recruit patients with moderate to severe degrees of knee OA. PRP will be injected into the knee joint and the pes anserine tendons. Simultaneous NPT will also be performed to the genicular nerves. The effectiveness will be examined using proteomics, isokinetic measurements and functional scale evaluations. Synovial fluid (SF) is in direct contact with the cartilage and synovium, protein biomarkers related to the disease pathophysiology of knee OA are contained within the SF and will be used for proteomic analysis. Patients will receive monthly injections for a total of 3 months. In short, if inflammatory proteins in the SF are not reduced after PRP injections, this indicates that PRP is not a good treatment choice for patients with moderate to severe degrees of knee OA. If inflammatory protein concentrations are further increased after NPT as patients may start strenuous exercises with reduced knee pain, more knee joint destruction may result.
Detailed Description
Patients will receive monthly injections for a total of 3 months. In short, if inflammatory proteins in the SF are not reduced after PRP injections, this indicates that PRP is not a good treatment choice for patients with moderate to severe degrees of knee OA. If inflammatory protein concentrations are further increased after NPT as patients may start strenuous exercises with reduced knee pain, more knee joint destruction may result. This signifies that NPT has pain reduction effect only and is not a viable treatment option. Roentgenograms may not show immediate signs of increased degeneration on the knee joints, but SF proteomic findings can provide us with evidences suggesting whether there is ongoing knee joint destruction. Upon the completion of this study, adequate scientific evidences will be gathered to know whether simultaneous PRP and NPT injections is a feasible option in treating patients with moderate to severe degrees of knee OA.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Knee Osteoarthritis
Keywords
platelet rich plasma; neural prolotherapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
Patients are divided into two groups. One group receiving PRP injections only. One group receiving PRP plus neural prolotherapy injections.
Masking
None (Open Label)
Enrollment
24 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Receiving PRP injections or PRP plus neural prolotherapy
Arm Type
Other
Arm Description
PRP injection into the knee joint and pes anserinus complex. Dextrose solution to the genicular nerves.
Intervention Type
Other
Intervention Name(s)
Autologous platelet rich plasma and dextrose solution.
Intervention Description
Autologous platelet rich plasma are injected into the knee joint and pes anserinus complex.
Dextrose solutions are injected to the genicular nerves.
Primary Outcome Measure Information:
Title
Lequesne knee osteoarthritis questionnaire
Description
Lequesne knee osteoarthritis functional index which includes distance, pain, and function.
Time Frame
About 10 minutes are required to evaluate the score of LeQuesne index.
Title
Two-dimensional electrophoresis (proteomics)
Description
Hundreds of protein spots can be viewed on 2-dimensional electrophoresis gels. The intensity of each spot represents protein concentration.
Time Frame
Two days are required to measure the protein band intensities on the gels.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients suffered from chronic unilateral knee pain for more than 4 months and with roentgenogram degenerative findings of grades 3 and 4 on the Kellgren-Lawrence Classification of Osteoarthritis scale (meaning moderate to severe degrees of knee OA) will be recruited.
The volume of the SF in the supra-patellar bursa region is enough (at least 2 mm thickness in bursa fluid as measured by ultrasound) to be aspirated via ultrasound guidance.
Small volume of SF will be aspirated first and sent for SF analysis. SF showing evidences of crystals suggesting possible gouty arthritis and infection will not be included in this study.
Patient has previously received oral NSAIDs and physical modality treatments but WITHOUT any obvious improvements in knee pain and function.
The usage of musculoskeletal ultrasound to confirm that the supra-patellar bursa is in communication with the synovial cavity of the knee joint. This is to prevent the aspiration of isolated cystic lesion at the supra-patellar region.
Exclusion Criteria:
Total obliteration of knee joint as shown on the roentgenogram images.
Patient has systemic disorders such as diabetes, rheumatoid arthritis, major axial deviation of the knee joint (varus >5°, valgus >5°), hematological diseases (coagulopathy), severe cardiovascular diseases, infections, and immune-depression.
Patients in therapy with anticoagulants, and taking NSAIDs within the 5 days before blood harvest.
Patients with hemoglobin value of less than 11 g/dl, and platelet counts of less than 150,000/mm3.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shu-Yi Tseng
Phone
03-3196200
Ext
3706
Email
tsengshui@cgmh.org.tw
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carl P.C. Chen, MD, PhD
Organizational Affiliation
Chang Gung Memorial Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chang Gung Memorial Hospital
City
Taoyuan
ZIP/Postal Code
33343
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shu-Yi Tseng
Phone
03-3196200
Ext
3706
Email
tsengshui@cgmh.org.tw
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Platelet Rich Plasma and Neural Prolotherapy Injections in Treating Knee Osteoarthritis
We'll reach out to this number within 24 hrs